Do Heart-Strengthening drugs actually help in shock? major trial aims to find out
NCT ID NCT05267886
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether drugs that increase the heart's pumping ability (inotropes) benefit patients in cardiogenic shock, a life-threatening condition where the heart can't pump enough blood. About 346 critically ill adults will receive either dobutamine, milrinone, or a placebo (saline). The main goal is to see if these drugs reduce death or serious complications within the first 12 hours. After that, doctors can choose any treatment. The trial is double-blind, so neither patients nor doctors know who gets the real drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dobutamine or Milrinone (heart-pumping drugs)
- What this could lead to
- If it works, this could show that inotropes improve survival and reduce complications in cardiogenic shock, guiding standard care.
- What could go wrong
- This is a Phase 4 trial, but the drugs are already used in practice. The placebo group may worsen, and results may not apply to all shock types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHOCK, CARDIOGENIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hamilton Health Sciences
RECRUITINGHamilton, Ontario, L8L 2X2, Canada
-
Mayo Clinic
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
-
University of Ottawa Heart Institute
RECRUITINGOttawa, Ontario, K1Y4W7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.